| Molecular markers to identify patients at risk for recurrence after primary treatment for prostate cancer. | |
| | |
MedLine Citation:
|
PMID: 14747039 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Accurate prognostication is a prerequisite for accurate therapeutics and management of prostate cancer because indolent tumors may require no intervention, whereas aggressive tumors lead to patient mortality. There is a critical need to define these subgroups of patients with prostate cancer differing in clinical outcome. Prognostic nomograms based on clinical data provide useful predictions of clinical states and outcomes, but they need further refinements to improve accuracy and universality. Genomic and proteomic analyses have provided many novel markers that may help define prognostic parameters based on the underlying biology of prostate cancer progression at the molecular level. These molecular markers are likely to augment traditional prognostic modalities by providing a set of molecularly defined and quantifiable variables. Encompassing the genome, transcriptome, and proteome of prostate cancer will likely provide "molecular signatures" that will bridge prognostication, prediction, and treatment in a single continuum. |
| | |
Authors:
|
Chandan Kumar-Sinha; Arul M Chinnaiyan |
Related Documents
:
|
21368659 - Long-term remission of an advanced recurrent endometrial cancer in a heavily pretreated... 21704809 - Screening for pancreatic cancer in a high-risk population with serum ca 19-9 and target... 20383179 - Integrating high-throughput technologies in the quest for effective biomarkers for ovar... 20371489 - Cancer sequencing gets a little more personal. 15920529 - From signatures to models: understanding cancer using microarrays. 16874019 - Links between biology, prognosis and prediction of response to chemotherapy in colorect... 22987949 - New insights into pancreatic cancer biology. 10668059 - A pilot study of interpersonal psychotherapy by telephone with cancer patients and thei... 23008529 - Diet and cancer. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.; Review |
Journal Detail:
|
Title: Urology Volume: 62 Suppl 1 ISSN: 1527-9995 ISO Abbreviation: Urology Publication Date: 2003 Dec |
Date Detail:
|
Created Date: 2004-01-28 Completed Date: 2004-04-16 Revised Date: 2007-11-14 |
Medline Journal Info:
|
Nlm Unique ID: 0366151 Medline TA: Urology Country: United States |
Other Details:
|
Languages: eng Pagination: 19-35 Citation Subset: IM |
Affiliation:
|
Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109-0602, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adenocarcinoma
/
blood,
chemistry*,
genetics,
therapy Algorithms Apoptosis Blood Proteins / analysis Cell Division Chromosomes, Human, Pair 8 / ultrastructure Disease Progression Gene Expression Profiling Humans Male Neoplasm Metastasis Neoplasm Proteins / analysis* Neoplasm Recurrence, Local Oligonucleotide Array Sequence Analysis Prognosis Prostatic Neoplasms / blood, chemistry*, genetics, therapy Proteomics Tumor Markers, Biological / analysis* |
| Grant Support | |
ID/Acronym/Agency:
|
P50 CA69568/CA/NCI NIH HHS; R01 CA97063/CA/NCI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Blood Proteins; 0/Neoplasm Proteins; 0/Tumor Markers, Biological |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Use of nomograms to predict the risk of disease recurrence after definitive local therapy for prosta...
Next Document: Use of neoadjuvant and adjuvant therapy to prevent or delay recurrence of prostate cancer in patient...